← All organizations
Highest phase reached
Phase 3
First clinical trial
Oct 1, 1993First marketed drug
May 28, 2010First NDA
May 28, 2010Last known activity
Nov 30, 2021
Timeline
1980s
- Jan 1, 1988
Cato Research— Founded
2010s
- May 28, 2010
hexyl 5-aminolevulinate— NDA Organization
Drugs by trial phase (18 distinct, 32 trials)
Phase 3 (3 own, 0 via acquisition)
Phase 2 (8 own, 0 via acquisition)
Phase 1 (7 own, 0 via acquisition)
Indications
Approved for
Studied for
- Abdominal Pain
- Adenocarcinoma
- Anemia, Sickle Cell
- Colorectal Neoplasms
- Constipation
- Diabetic Foot
- Digestive System Diseases
- Esophageal Neoplasms
- Foot Ulcer
- Gastrointestinal Diseases
- Genetic Diseases, Inborn
- Ileus
- Intestinal Diseases
- Irritable Bowel Syndrome
- Jaundice
- Leukemia
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Molluscum Contagiosum
- Myelodysplastic Syndromes
- Neoplasms
- Neuralgia
- Pancreatic Neoplasms
- Pneumonia
- Preleukemia
- Sepsis
- Soft Tissue Injuries
- Stomach Neoplasms
- Syndrome
- Toxemia
- Ulcer
- Wounds and Injuries
Marketed drugs (2)
Recent trials (33)
- NCT05071846CollaboratorPhase 1Nov 30, 2021
- NCT04855435CollaboratorPhase 1Apr 12, 2021
- NCT04751786CollaboratorPhase 1Jan 11, 2021
- NCT04612413CollaboratorPhase 2Nov 15, 2020
- NCT03186378CollaboratorPhase 2Jun 8, 2017
- NCT02807961CollaboratorPhase 1Aug 1, 2016
- NCT02602184CollaboratorPhase 2Nov 1, 2015
- NCT02232893CollaboratorPhase 2Oct 1, 2014
- NCT01890837CollaboratorPhase 1/Phase 2Aug 1, 2013
- NCT01597401CollaboratorPhase 1May 1, 2012
- NCT01483846CollaboratorPhase 1Dec 1, 2011
- NCT01348152CollaboratorPhase 2Sep 1, 2011
- NCT01139216CollaboratorPhase 1/Phase 2Aug 1, 2010
- NCT00926068CollaboratorPhase 2Feb 1, 2010
- NCT00871325CollaboratorPhase 1/Phase 2Jun 1, 2009
Details
- Founded
- Durham, NC, US Jan 1, 1988
- First NDA
- May 28, 2010
- Last known activity
- Nov 30, 2021
Designations held
- Orphan drug
- Priority review